Somatic mutation of DNAH genes implicated higher chemotherapy response rate in gastric adenocarcinoma patients
Adult
Male
0301 basic medicine
DNAH mutation
Chemotherapy response
Adenocarcinoma
Biomarkers, Pharmacological
Disease-Free Survival
Cohort Studies
03 medical and health sciences
Stomach Neoplasms
Antineoplastic Combined Chemotherapy Protocols
Exome Sequencing
Biomarkers, Tumor
Humans
Aged
Aged, 80 and over
Research
R
Dyneins
TCGA
Middle Aged
Prognosis
3. Good health
Treatment Outcome
Multigene Family
Mutation
Medicine
Female
Gastric cancer
DOI:
10.1186/s12967-019-1867-6
Publication Date:
2019-04-03T12:03:11Z
AUTHORS (9)
ABSTRACT
The dynein axonemal heavy chain (DNAH) family of genes encode the chain, which is involved in cell motility. Genomic variations DNAH members have been frequently reported diverse kinds malignant tumors. In this study, we analyzed genomic database to evaluate mutation status gastric adenocarcinoma and further identified significance mutant as effective molecular biomarkers for predicting chemotherapy response cancer patients. We clinical data patients published Cancer Genome Atlas (TCGA) project. Data on response, overall survival (OS) chemotherapy-free were retrieved. Then, verified results via targeted sequencing with similar characteristics but different chemotherapeutic outcomes. total, 132 undergoing treatment from TCGA included our study. Somatic mutations all 13 associated responses. Compared wild-type (n = 59), a significantly higher proportion those 73) (55.9% vs 80.8%) responded (P 0.002). Moreover, correlated better OS 0.027), fluoropyrimidine-free 0.048) platinum-free 0.014). was an independent risk factor 0.015), 0.015) 0.011). somatic 27 (42.2%) 64 stage III receiving fluoropyrimidine-based by exon strict screening conditions. own cohort, 32) than had good prognosis (OS > 48 months) (70.4% 35.1%) 0.005). Dynein gene contribute positively sensitivity
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (36)
CITATIONS (23)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....